ClinicalTrials.gg
CompletedNCT04004611SHINE-1Updated Mar 26, 2024Results posted

A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)

A Phase 2 interventional study of Mirikizumab in Ulcerative Colitis, sponsored by Eli Lilly and Company. Completed at 37 sites in 5 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-03-26.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing mirikizumab in Colitis, Ulcerative — 4 open to participants now, 5 under way, 2 of them phase 3. mirikizumab · Colitis, Ulcerative.

Enrollment
12th of 13
26 · median 172
Started
2020
the only one that year
Phase 2
2 of 13
none open now
Registered
5th of 13
by date
Lead sponsor
9 of 13
Eli Lilly and Company

Among the 13 studies testing mirikizumab in Colitis, Ulcerative, this one is the 12th largest by enrollment, is the only one that started in 2020, is one of 2 in phase 2, and was the 5th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

4 of the 13 studies testing mirikizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About mirikizumab

mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing mirikizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

This study was designed to evaluate how the body processes and removes mirikizumab. The study also evaluated safety and disease response in pediatric participants with UC taking mirikizumab. The study lasted about 52 weeks and included up to 18 visits.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Interleukin-23 (IL-23) antibody
  • IL-23p19
  • Pediatric
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants weighing >10 kg
  • Participants must have a diagnosis of ulcerative colitis for at least 3 months before the planned start date for the study medications
  • Participants must have moderately to severely active UC as defined by a Modified Mayo Score (MMS) within 14 days before the first dose of study treatment
  • Participants must have evidence of UC extending proximal to the rectum
  • Participants must have demonstrated an inadequate response to, a loss of response to, or an intolerance to , immunomodulators, Janus kinase inhibitor (JAK-inhibitor) or to biologic therapies for UC

Exclusion criteria

Exclusion Criteria:

  • Participants must not have a current diagnosis of Crohn's disease, inflammatory bowel disease-unclassified (indeterminate colitis), ulcerative proctitis, or primary sclerosing cholangitis
  • Participants must not have had surgery to remove part of their colon
  • Participants must not have current evidence of toxic megacolon
  • Participants must not have received any of the following for treatment of UC: cyclosporine or thalidomide within 30 days of screening; enemas, corticosteroid suppositories, or topical treatment with 5-aminosalicyclic acid within 1 week of screening endoscopy
  • Participants must not have had an inadequate response to Interleukin-12 p40 subunit antibody (anti-IL12p40) (e.g. ustekinumab) or had prior exposure to anti-IL-23p19 antibodies (e.g. risankizumab, brazikumab, guselkumab or tildrakizumab)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Open Label (OL) Induction Period: 5 milligram per kilogram (mg/kg) Miri intravenous (IV)

    Participants (≤40 kg weight) received 5 mg/kg mirikizumab given as an IV infusion every 4 weeks (Q4W) on weeks 0, 4, 8 for 12 weeks.

    Drug: Mirikizumab

  • Experimental
    Open Label Induction Period: 10 mg/kg Miri IV

    Participants (≤40 kg weight) received 10 mg/kg mirikizumab given as an IV infusion Q4W on weeks 0, 4, 8 for 12 weeks.

    Drug: Mirikizumab

  • Experimental
    Open Label Induction Period: 300 mg Miri IV

    Participants (\>40 kg weight) received 300 mg mirikizumab given as an IV infusion Q4W on weeks 0, 4, 8 for 12 weeks.

    Drug: Mirikizumab

  • Experimental
    Open Label Maintenance Period: 50 mg Miri subcutaneous (SC)

    Participants (≤20 kg weight) who were responders to mirikizumab at week 12 in induction received 50 mg subcutaneously (SC) Q4W from week 12 through week 48 or until loss of response was confirmed.

    Drug: Mirikizumab

  • Experimental
    Open Label Maintenance Period: 100 mg Miri SC

    Participants (\>20 to ≤40 kg weight) who were responders to mirikizumab at week 12 in induction received 100 mg SC Q4W from week 12 through week 48 or until loss of response was confirmed.

    Drug: Mirikizumab

  • Experimental
    Open Label Maintenance Period: 200 mg Miri SC

    Participants (\>40 kg weight) who were responders to mirikizumab at week 12 in induction received 200 mg SC Q4W from week 12 through week 48 or until loss of response was confirmed.

    Drug: Mirikizumab

  • Experimental
    Open Label Maintenance Period: Non-Responders: 10 mg/kg Miri IV/ 50 mg Miri SC

    Participants (≤40 kg) who were non responders to miri at Week 12 in induction received 10 mg SC Q4W for 12 weeks or discontinued after repeat induction, and then received 50 mg miri (≤20 kg weight) SC Q4W through week 48 or until loss of response was confirmed.

    Drug: Mirikizumab

  • Experimental
    Open Label Maintenance Period: Non-Responders: 10 mg/kg Miri IV/100 mg Miri SC

    Participants (≤40 kg) who were non responders to miri at week 12 in induction received 10 mg SC Q4W for 12 weeks or discontinued after repeat induction, and then received 100 mg miri (\>20 to ≤40 kg weight) SC Q4W through week 48 or until loss of response was confirmed.

    Drug: Mirikizumab

  • Experimental
    Open Label Maintenance Period: Non-Responders: 300 mg Miri IV /200 mg Miri SC

    Participants (\>40 kg) who were non responders to miri at week 12 in induction received 300 mg SC Q4W for 12 weeks or discontinued after repeat induction, then received 200 mg miri SC Q4W through week 48 or until loss of response was confirmed.

    Drug: Mirikizumab

Interventions

  • Administered IV and SC

    Also known as: LY3074828

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Clearance of Mirikizumab

    Clearance of mirikizumab was evaluated. The PK of mirikizumab is characterized at interim analysis points using mixed-effect (population PK) modelling approaches using the available induction and maintenance mirikizumab concentration data.

    Time frame: Predose on week 4, 8, 12,16, 24, 36, 52 and post dose on week 0 and 8

Secondary outcomes

  1. Percentage of Participants in Clinical Remission

    Clinical remission at week 52 is defined as achieving a 9-point modified Mayo score (MMS) for rectal bleeding (RB) = 0, stool frequency (SF) = 0 or 1 and endoscopy (ES) = 0 or 1 (excluding friability). The MMS is a composite score of ulcerative colitis disease activity calculated as the sum of three subscores: SF subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); RB subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed); ES subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding,ulceration.

    Time frame: Week 52

  2. Percentage of Participants in Clinical Response

    Clinical response at week 52 is defined as a decrease in the 9-point modified Mayo score (MMS) \[rectal bleeding, stool frequency and the endoscopic findings\] inclusive of ≥2 points and ≥30% from baseline with either a decrease of rectal bleeding subscore of ≥1 or rectal bleeding subscore of 0 or 1. The MMS is a composite score of ulcerative colitis disease activity calculated as the sum of three subscores: SF subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); RB subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed); ES subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration)

    Time frame: Week 52

  3. Percentage of Participants Who Are in MMS Clinical Remission Without the Use of Corticosteroids

    Corticosteroid-free clinical remission was defined as an SF subscore = 0 or 1, RB subscore = 0, ES ≤ 1 (excluding friability), and have not received corticosteroids for ≥ 12 weeks in the 52-Week Treatment Period. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

    Time frame: Week 52

  4. Percentage of Participants in Clinical Remission Based on the Pediatric Ulcerative Colitis Activity Index (PUCAI)

    The PUCAI is a clinician-administered, 6-item questionnaire that measures: abdominal pain; RB; stool consistency; number of stools; nocturnal stools; and activity level. For PUCAI score all items are answered as an average over the 'past 2 days'. A total disease activity score is calculated from 0 to 85, with Severe 65-85; Moderate:35-60; Mild:10-30, and None:\<10. The clinician will record the participant or caregiver/legal guardian responses for the PUCAI electronically as source data in the tablet device at appropriate visits. PUCAI clinical remission is defined as a PUCAI score of \<10 points.

    Time frame: Week 52

  5. Percentage of Participants in Clinical Response Based on the PUCAI

    PUCAI clinical response is defined as a reduction in baseline PUCAI score of ≥20 points.

    Time frame: Week 52

  6. Percentage of Participants in Endoscopic Remission

    Endoscopic remission at week 52 is defined as achieving a Mayo endoscopic subscore of 0 or 1 (excluding friability) at Week 52. ES subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration).

    Time frame: Week 52

  7. Percentage of Participants in Symptomatic Remission

    Symptomatic remission at week 52 is defined as a Mayo score for RB=0, SF=0 or 1 with ≥ 1 point decrease from baseline. SF subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal). RB subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed).

    Time frame: Week 52

  8. Height Velocity (in Centimeters/Year)

    Observed height velocity by gender and age group was calculated. Age groups for which this was summarized were 2 to \<8, 8 to \<12, and 12 to \<18. Observed height velocity by gender and age group was calculated at baseline according to the following formula: (Present Height \[cm\] - Previous Height \[cm\])/Interval (months) Between Measurements × 12.

    Time frame: Week 52

  9. Change From Baseline in Body Weight

    Change from Baseline in body weight by gender and age group was calculated.

    Time frame: Baseline, Week 52

  10. Percentage of Participants With Histologic-Endoscopic Mucosal Remission

    Histologic-endoscopic mucosal remission is defined as achieving both histologic remission and endoscopic remission. Histologic remission is defined as Geboes histological subscores of 0 for parameters: 2B (neutrophils in lamina propria), 3 (neutrophils in epithelium), 4 (crypt destruction), and 5 (erosion or ulceration).

    Time frame: Week 52

  11. Change From Baseline in 7-day Average of Abdominal Pain Numeric Rating Scale (NRS) Score at Week 12

    The Abdominal Pain NRS is a single participant-reported item that measures the "worst abdominal pain in the past 24 hours" using a 6-point scale ranging from 0 (no pain) to 5 (worst possible pain) for 8-11 years old, and 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain) for children \< 8 years old as completed by a caregiver and those 12-17 years old. Abdominal Pain NRS Score is calculated by averaging data from all available daily diary entries of abdominal pain NRS for a 7 day period. A negative change from baseline indicates improvement in the participant's Abdominal Pain NRS.

    Time frame: Baseline, Week 12

  12. Change From Baseline in 7-day Average of Abdominal Pain NRS Score at Week 52

    The Abdominal Pain NRS is a single participant-reported item that measures the "worst abdominal pain in the past 24 hours" using a 6-point scale ranging from 0 (no pain) to 5 (worst possible pain) for 8-11 years old, and 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain) for children \< 8 years old as completed by a caregiver and those 12-17 years old. Abdominal Pain NRS Score is calculated by averaging data from all available daily diary entries of abdominal pain NRS for a 7 day period. A negative change from baseline indicates improvement in the participant's Abdominal Pain NRS.

    Time frame: Baseline, Week 52

07

Results

Posted Oct 27, 2023

Participant flow

OL Induction Period (Wk 0-12)
Participant flow — OL Induction Period (Wk 0-12)
MilestoneOpen Label (OL) Induction Period: 5 Milligram Per Kilogram (mg/kg) Miri IVOL Induction Period: 10 mg/kg Miri IVOL Induction Period: 300 mg Miri IVOL Maintenance Period: 50 mg Miri Subcutaneous (SC)OL Maintenance Period: 100 mg Miri SCOL Maintenance Period: 200 mg Miri SCOL Maintenance Period: NR: 10 mg/kg Miri IV/50 mg Miri SCOL Maintenance Period: NR: 10 mg/kg Miri IV/100 mg Miri SCOL Maintenance Period: NR: 300 mg Miri IV /200 mg Miri SC
Started10511000000
Completed10511000000
Not completed000000000
OL Maintenance Period (Wk 12-52)
Participant flow — OL Maintenance Period (Wk 12-52)
MilestoneOpen Label (OL) Induction Period: 5 Milligram Per Kilogram (mg/kg) Miri IVOL Induction Period: 10 mg/kg Miri IVOL Induction Period: 300 mg Miri IVOL Maintenance Period: 50 mg Miri Subcutaneous (SC)OL Maintenance Period: 100 mg Miri SCOL Maintenance Period: 200 mg Miri SCOL Maintenance Period: NR: 10 mg/kg Miri IV/50 mg Miri SCOL Maintenance Period: NR: 10 mg/kg Miri IV/100 mg Miri SCOL Maintenance Period: NR: 300 mg Miri IV /200 mg Miri SC
Started000189116
Completed000178012
Not completed000011104
Withdrew: Adverse event000000001
Withdrew: Lack of efficacy000001103
Withdrew: Withdrawal by parent or guardian000010000
OL Induction and Maintenance Period
Participant flow — OL Induction and Maintenance Period
MilestoneOpen Label (OL) Induction Period: 5 Milligram Per Kilogram (mg/kg) Miri IVOL Induction Period: 10 mg/kg Miri IVOL Induction Period: 300 mg Miri IVOL Maintenance Period: 50 mg Miri Subcutaneous (SC)OL Maintenance Period: 100 mg Miri SCOL Maintenance Period: 200 mg Miri SCOL Maintenance Period: NR: 10 mg/kg Miri IV/50 mg Miri SCOL Maintenance Period: NR: 10 mg/kg Miri IV/100 mg Miri SCOL Maintenance Period: NR: 300 mg Miri IV /200 mg Miri SC
Started10511000000
Completed946000000
Not completed115000000
Withdrew: Adverse event001000000
Withdrew: Lack of efficacy104000000
Withdrew: Withdrawal by parent or guardian010000000

Outcome measures

PrimaryPharmacokinetics (PK): Clearance of Mirikizumab

Clearance of mirikizumab was evaluated. The PK of mirikizumab is characterized at interim analysis points using mixed-effect (population PK) modelling approaches using the available induction and maintenance mirikizumab concentration data.

Time frame:
Predose on week 4, 8, 12,16, 24, 36, 52 and post dose on week 0 and 8
Reported as:
Geometric mean · Liters per hour per kilogram (L/hr/kg)
Pharmacokinetics (PK): Clearance of Mirikizumab
Liters per hour per kilogram (L/hr/kg)Mirikizumab
Pharmacokinetics (PK): Clearance of Mirikizumab0.000190 ± 59.74
SecondaryPercentage of Participants in Clinical Remission

Clinical remission at week 52 is defined as achieving a 9-point modified Mayo score (MMS) for rectal bleeding (RB) = 0, stool frequency (SF) = 0 or 1 and endoscopy (ES) = 0 or 1 (excluding friability). The MMS is a composite score of ulcerative colitis disease activity calculated as the sum of three subscores: SF subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); RB subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed); ES subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding,ulceration.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants in Clinical Remission
percentage of participantsMaintenance Period: 50 mg Miri SC Q4WMaintenance Period: 100 mg Miri SC Q4WMaintenance Period: 200 mg Miri SC Q4WMaintenance Period: 10 mg/kg Miri IV/50 mg Miri SCMaintenance Period: 10 mg/kg Miri IV/100 mg Miri SCMaintenance Period: 300 mg Miri IV/200 mg Miri SC
Percentage of Participants in Clinical Remission0.0 (0.0 to 79.3)62.5 (30.6 to 86.3)55.6 (26.7 to 81.1)0.0 (0.0 to 79.3)0.0 (0.0 to 79.3)0.0 (0.0 to 39.0)
SecondaryPercentage of Participants in Clinical Response

Clinical response at week 52 is defined as a decrease in the 9-point modified Mayo score (MMS) \[rectal bleeding, stool frequency and the endoscopic findings\] inclusive of ≥2 points and ≥30% from baseline with either a decrease of rectal bleeding subscore of ≥1 or rectal bleeding subscore of 0 or 1. The MMS is a composite score of ulcerative colitis disease activity calculated as the sum of three subscores: SF subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); RB subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed); ES subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration)

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants in Clinical Response
percentage of participantsMaintenance Period: 50 mg Miri SC Q4WMaintenance Period: 100 mg Miri SC Q4WMaintenance Period: 200 mg Miri SC Q4WMaintenance Period: 10 mg/kg Miri IV/50 mg Miri SCMaintenance Period: 10 mg/kg Miri IV/100 mg Miri SCMaintenance Period: 300 mg Miri IV/200 mg Miri SC
Percentage of Participants in Clinical Response0.0 (0.0 to 79.3)75.0 (40.9 to 92.9)88.9 (56.5 to 98.0)0.0 (0.0 to 79.3)0.0 (0.0 to 79.3)0.0 (0.0 to 39.0)
SecondaryPercentage of Participants Who Are in MMS Clinical Remission Without the Use of Corticosteroids

Corticosteroid-free clinical remission was defined as an SF subscore = 0 or 1, RB subscore = 0, ES ≤ 1 (excluding friability), and have not received corticosteroids for ≥ 12 weeks in the 52-Week Treatment Period. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Are in MMS Clinical Remission Without the Use of Corticosteroids
percentage of participantsMaintenance Period: 50 mg Miri SC Q4WMaintenance Period: 100 mg Miri SC Q4WMaintenance Period: 200 mg Miri SC Q4WMaintenance Period: 10 mg/kg Miri IV/50 mg Miri SCMaintenance Period: 10 mg/kg Miri IV/ 100 mg Miri SCMaintenance Period: 300 mg Miri IV/ 200 mg Miri SC
Percentage of Participants Who Are in MMS Clinical Remission Without the Use of Corticosteroids0.0 (0.0 to 79.3)62.5 (30.6 to 86.3)55.6 (26.7 to 81.1)0.0 (0.0 to 79.3)0.0 (0.0 to 79.3)0.0 (0.0 to 39.0)
SecondaryPercentage of Participants in Clinical Remission Based on the Pediatric Ulcerative Colitis Activity Index (PUCAI)

The PUCAI is a clinician-administered, 6-item questionnaire that measures: abdominal pain; RB; stool consistency; number of stools; nocturnal stools; and activity level. For PUCAI score all items are answered as an average over the 'past 2 days'. A total disease activity score is calculated from 0 to 85, with Severe 65-85; Moderate:35-60; Mild:10-30, and None:\<10. The clinician will record the participant or caregiver/legal guardian responses for the PUCAI electronically as source data in the tablet device at appropriate visits. PUCAI clinical remission is defined as a PUCAI score of \<10 points.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants in Clinical Remission Based on the Pediatric Ulcerative Colitis Activity Index (PUCAI)
percentage of participantsMaintenance Period: 50 mg Miri SC Q4WMaintenance Period: 100 mg Miri SC Q4WMaintenance Period: 200 mg Miri SC Q4WMaintenance Period: 10 mg/kg Miri IV/50 mg Miri SCMaintenance Period: 10 mg/kg Miri IV/100 mg Miri SCMaintenance Period: 300 mg Miri IV/200 mg Miri SC
Percentage of Participants in Clinical Remission Based on the Pediatric Ulcerative Colitis Activity Index (PUCAI)0.0 (0.0 to 79.3)75.0 (40.9 to 92.9)77.8 (45.3 to 93.7)0.0 (0.0 to 79.3)0.0 (0.0 to 79.3)0.0 (0.0 to 39.0)
SecondaryPercentage of Participants in Clinical Response Based on the PUCAI

PUCAI clinical response is defined as a reduction in baseline PUCAI score of ≥20 points.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants in Clinical Response Based on the PUCAI
percentage of participantsMaintenance Period: 50 mg Miri SC Q4WMaintenance Period: 100 mg Miri SC Q4WMaintenance Period: 200 mg Miri SC Q4WMaintenance Period: 10 mg/kg Miri IV/50 mg Miri SCMaintenance Period: 10 mg/kg Miri IV/100 mg Miri SCMaintenance Period: 300 mg Miri IV/200 mg Miri SC
Percentage of Participants in Clinical Response Based on the PUCAI0.0 (0.0 to 79.3)75.0 (40.9 to 92.9)88.9 (56.5 to 98.0)0.0 (0.0 to 79.3)0.0 (0.0 to 79.3)0.0 (0.0 to 39.0)
SecondaryPercentage of Participants in Endoscopic Remission

Endoscopic remission at week 52 is defined as achieving a Mayo endoscopic subscore of 0 or 1 (excluding friability) at Week 52. ES subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration).

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants in Endoscopic Remission
percentage of participantsMaintenance Period: 50 mg Miri SC Q4WMaintenance Period: 100 mg Miri SC Q4WMaintenance Period: 200 mg Miri SC Q4WMaintenance Period: 10 mg/kg Miri IV/50 mg Miri SCMaintenance Period: 10 mg/kg Miri IV/100 mg Miri SCMaintenance Period: 300 mg Miri IV/200 mg Miri SC
Percentage of Participants in Endoscopic Remission0.0 (0.0 to 79.3)62.5 (30.6 to 86.3)55.6 (26.7 to 81.1)0.0 (0.0 to 79.3)0.0 (0.0 to 79.3)0.0 (0.0 to 39.0)
SecondaryPercentage of Participants in Symptomatic Remission

Symptomatic remission at week 52 is defined as a Mayo score for RB=0, SF=0 or 1 with ≥ 1 point decrease from baseline. SF subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal). RB subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed).

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants in Symptomatic Remission
percentage of participantsMaintenance Period: 50 mg Miri SC Q4WMaintenance Period: 100 mg Miri SC Q4WMaintenance Period: 200 mg Miri SC Q4WMaintenance Period: 10 mg/kg Miri IV/50 mg Miri SCMaintenance Period: 10 mg/kg Miri IV/100 mg Miri SCMaintenance Period: 300 mg Miri IV/200 mg Miri SC
Percentage of Participants in Symptomatic Remission0.0 (0.0 to 79.3)75.0 (40.9 to 92.9)66.7 (35.4 to 87.9)0.0 (0.0 to 79.3)0.0 (0.0 to 79.3)0.0 (0.0 to 39.0)
SecondaryHeight Velocity (in Centimeters/Year)

Observed height velocity by gender and age group was calculated. Age groups for which this was summarized were 2 to \<8, 8 to \<12, and 12 to \<18. Observed height velocity by gender and age group was calculated at baseline according to the following formula: (Present Height \[cm\] - Previous Height \[cm\])/Interval (months) Between Measurements × 12.

Time frame:
Week 52
Reported as:
Mean · centimeter per year (cm/year)
Height Velocity (in Centimeters/Year)
centimeter per year (cm/year)OL Induction and Maintenance Period: 5 mg/kg Miri IVOL Induction and Maintenance Period: 10 mg/kg Miri IVOL Induction and Maintenance Period: 300 mg Miri IV
Female: 2 - <8 yearsNA ± NA——
Female: 8 - <12 years8.65 ± 3.2——
Female: 12 - <18 years4.54 ± 4.24.14 ± 1.32.97 ± 0.2
Male: 2 - <8 yearsNA ± NA——
Male: 8 - <12 years—NA ± NA—
Male: 12 - <18 years12.67 ± 1.0NA ± NA3.65 ± 4.3
SecondaryChange From Baseline in Body Weight

Change from Baseline in body weight by gender and age group was calculated.

Time frame:
Baseline, Week 52
Reported as:
Mean · kg
Change From Baseline in Body Weight
kgOL Induction and Maintenance Period: 5 mg/kg Miri IVOL Induction and Maintenance Period: 10 mg/kg Miri IVOL Induction and Maintenance Period: 300 mg Miri IV
Female: 2 - <8 yearsNA ± NA——
Female: 8 - <12 years8 ± 1.1——
Female: 12 - <18 years9 ± 7.19 ± 3.58 ± 2.7
Male: 2 - <8 yearsNA ± NA——
Male: 8 - <12 years—NA ± NA—
Male: 12 - <18 years13 ± 11.6NA ± NA2 ± 3.2
SecondaryPercentage of Participants With Histologic-Endoscopic Mucosal Remission

Histologic-endoscopic mucosal remission is defined as achieving both histologic remission and endoscopic remission. Histologic remission is defined as Geboes histological subscores of 0 for parameters: 2B (neutrophils in lamina propria), 3 (neutrophils in epithelium), 4 (crypt destruction), and 5 (erosion or ulceration).

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Histologic-Endoscopic Mucosal Remission
percentage of participantsMaintenance Period: 50 mg Miri SC Q4WMaintenance Period: 100 mg Miri SC Q4WMaintenance Period: 200 mg Miri SC Q4WMaintenance Period: 10 mg/kg Miri IV/50 mg Miri SCMaintenance Period: 10 mg/kg Miri IV/100 mg Miri SCMaintenance Period: 300 mg Miri IV/200 mg Miri SC
Percentage of Participants With Histologic-Endoscopic Mucosal Remission0.0 (0.0 to 79.3)62.5 (30.6 to 86.3)44.4 (18.9 to 73.3)0.0 (0.0 to 79.3)0.0 (0.0 to 79.3)0.0 (0.0 to 39.0)
SecondaryChange From Baseline in 7-day Average of Abdominal Pain Numeric Rating Scale (NRS) Score at Week 12

The Abdominal Pain NRS is a single participant-reported item that measures the "worst abdominal pain in the past 24 hours" using a 6-point scale ranging from 0 (no pain) to 5 (worst possible pain) for 8-11 years old, and 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain) for children \< 8 years old as completed by a caregiver and those 12-17 years old. Abdominal Pain NRS Score is calculated by averaging data from all available daily diary entries of abdominal pain NRS for a 7 day period. A negative change from baseline indicates improvement in the participant's Abdominal Pain NRS.

Time frame:
Baseline, Week 12
Reported as:
Mean · score on a scale
Change From Baseline in 7-day Average of Abdominal Pain Numeric Rating Scale (NRS) Score at Week 12
score on a scaleOpen Label Induction Period: 5 mg/kg Miri IVOpen Label Induction Period: 10 mg/kg Miri IVOpen Label Induction Period: 300 mg Miri IV
2 - <8 years-3 ± 2.1——
8 - <12 years-3 ± 2.1NA ± NA—
12- <18 years-4 ± 2.7-2 ± 1.5-1 ± 2.8
SecondaryChange From Baseline in 7-day Average of Abdominal Pain NRS Score at Week 52

The Abdominal Pain NRS is a single participant-reported item that measures the "worst abdominal pain in the past 24 hours" using a 6-point scale ranging from 0 (no pain) to 5 (worst possible pain) for 8-11 years old, and 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain) for children \< 8 years old as completed by a caregiver and those 12-17 years old. Abdominal Pain NRS Score is calculated by averaging data from all available daily diary entries of abdominal pain NRS for a 7 day period. A negative change from baseline indicates improvement in the participant's Abdominal Pain NRS.

Time frame:
Baseline, Week 52
Reported as:
Mean · score on a scale
Change From Baseline in 7-day Average of Abdominal Pain NRS Score at Week 52
score on a scaleOL Maintenance Period: 50 mg Miri SCOL Maintenance Period: 100 mg Miri SCOL Maintenance Period: 200 mg Miri SCOL Maintenance Period: NR: 10 mg/kg Miri IV/50 mg Miri SCOL Maintenance Period: NR: 10 mg/kg Miri IV/100 mg Miri SCOL Maintenance Period: NR: 300 mg Miri IV /200 mg Miri SC
2 - <8 yearsNA ± NANA ± NA—0 ± 0——
8 - <12 years—-2 ± 1.0————
12- <18 years—-5 ± 3.1-4 ± 2.4—NA ± NA0 ± 2.6

Adverse events

Collected over Induction Period (Up to 12 Weeks), Induction and Maintenance Period (Up to 52 Weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OL Induction Period: 5 mg/kg Miri IV0/10 (0%)0/10 (0%)8/10 (80%)
OL Induction Period: 10 mg/kg Miri IV0/5 (0%)0/5 (0%)2/5 (40%)
OL Induction Period: 300 mg Miri IV0/11 (0%)0/11 (0%)8/11 (72.7%)
OL Induction and Maintenance Period: 5 mg/kg Miri IV0/10 (0%)0/10 (0%)9/10 (90%)
OL Induction and Maintenance Period: 10 mg/kg Miri IV0/5 (0%)2/5 (40%)5/5 (100%)
OL Induction and Maintenance Period: 300 mg Miri IV0/11 (0%)1/11 (9.1%)11/11 (100%)
Most frequent serious events
Most frequent serious events
EventOL Induction Period: 5 mg/kg Miri IVOL Induction Period: 10 mg/kg Miri IVOL Induction Period: 300 mg Miri IVOL Induction and Maintenance Period: 5 mg/kg Miri IVOL Induction and Maintenance Period: 10 mg/kg Miri IVOL Induction and Maintenance Period: 300 mg Miri IV
Appendicitis noninfectiveGastrointestinal disorders0/100/50/110/101/50/11
PseudarthrosisMusculoskeletal and connective tissue disorders0/100/50/110/101/50/11
Colitis ulcerativeGastrointestinal disorders0/100/50/110/100/51/11
Most frequent other events
Showing 10 of 71
Most frequent other events
EventOL Induction Period: 5 mg/kg Miri IVOL Induction Period: 10 mg/kg Miri IVOL Induction Period: 300 mg Miri IVOL Induction and Maintenance Period: 5 mg/kg Miri IVOL Induction and Maintenance Period: 10 mg/kg Miri IVOL Induction and Maintenance Period: 300 mg Miri IV
COVID-19Infections and infestations0/101/50/112/102/52/11
HeadacheNervous system disorders3/100/51/113/100/52/11
Injection site painGeneral disorders0/100/50/112/101/53/11
AnaemiaBlood and lymphatic system disorders0/101/50/110/101/50/11
Growth hormone deficiencyEndocrine disorders0/100/50/110/101/50/11
DyspepsiaGastrointestinal disorders0/100/50/110/101/50/11
VomitingGastrointestinal disorders1/100/51/112/100/51/11
Injection site erythemaGeneral disorders0/100/50/111/101/50/11
Injection site pruritusGeneral disorders0/100/50/111/101/50/11
Injection site reactionGeneral disorders0/100/50/111/101/50/11

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)OL Induction Period: 5 mg/kg Miri IVOL Induction Period: 10 mg/kg Miri IVOL Induction Period: 300 mg Miri IVTotal
Mean9.6 ± 4.2211.6 ± 1.1414.0 ± 1.2611.80 ± 3.37
Sex: Female, Male
Sex: Female, Male(Participants)OL Induction Period: 5 mg/kg Miri IVOL Induction Period: 10 mg/kg Miri IVOL Induction Period: 300 mg Miri IVTotal
Female63615
Male42511
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OL Induction Period: 5 mg/kg Miri IVOL Induction Period: 10 mg/kg Miri IVOL Induction Period: 300 mg Miri IVTotal
Hispanic or Latino3003
Not Hispanic or Latino23813
Unknown or Not Reported52310
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OL Induction Period: 5 mg/kg Miri IVOL Induction Period: 10 mg/kg Miri IVOL Induction Period: 300 mg Miri IVTotal
American Indian or Alaska Native0000
Asian4217
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White53917
More than one race1001
Unknown or Not Reported0011
Region of Enrollment
Region of Enrollment(Participants)OL Induction Period: 5 mg/kg Miri IVOL Induction Period: 10 mg/kg Miri IVOL Induction Period: 300 mg Miri IVTotal
Israel0011
Japan1214
South Korea4004
United States53917
08

Study locations

37 sites
  • Childrens Hospital of Orange County
    Orange, California 92868, United States
  • UCSF Medical Center at Mission Bay
    San Francisco, California 94158, United States
  • Children's Hospital of Colorado
    Denver, Colorado 80045, United States
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Children's Center for Digestive Health Care, LLC
    Atlanta, Georgia 30342, United States
  • University of Chicago Hospital
    Chicago, Illinois 60637, United States
  • Riley Hospital for Children
    Carmel, Indiana 46302, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • MGH for Children - Waltham
    Waltham, Massachusetts 02451, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Goryeb Children's Hospital / Atlantic Health System
    Morristown, New Jersey 07960, United States
  • Icahn Sch of Med at Mt. Sinai
    New York, New York 10029, United States
  • Cincinnati Childrens Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • The Abbigail Wexner Research Institute at Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • UPMC Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Cook Children's Hospital
    Fort Worth, Texas 76104, United States
  • Texas Childrens Hospital
    Houston, Texas 77030, United States
  • Pediatrics Specialists of Virginia
    Fairfax, Virginia 22031, United States
  • Children's Hospital of The King's Daughters Inc
    Norfolk, Virginia 23507, United States
  • Seattle Children's Hospital Research Foundation
    Seattle, Washington 98105, United States
  • University of Alberta Hospital
    Edmonton, Alberta T6G 1C9, Canada
  • IWK Health Centre
    Halifax, Nova Scotia B3K 6R8, Canada
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • Rambam Medical Center
    Haifa, 3109601, Israel
  • The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition; Shaare Zedek Medical Center
    Jerusalem, Israel
  • Schneider Children's Medical Center
    Petah Tiqva, 4920235, Israel
  • Kurume University Hospital
    Kurume, Fukuoka 830-0011, Japan
  • Saiseikai Yokohamashi Tobu Hospital
    Yokohama, Kanagawa 2308765, Japan
  • Saitama Children's Medical Center
    Saitama-shi, Saitama 330 8777, Japan
  • Juntendo University Hospital
    Bunkyo-ku, Tokyo 113-8431, Japan
  • Tokyo Medical and Dental University Hospital
    Bunkyō, Tokyo 113-8519, Japan
  • National Center For Child Health And Development
    Setagaya-ku, Tokyo 157-8535, Japan
  • Tokyo Medical University Hospital
    Shinjuku-ku, Tokyo 160-0023, Japan
  • Kyungpook National University Medical Center Chilgok Hospital
    Daegu, 41404, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 3080, Korea, Republic of
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Mar 2023, 33 months.

Results were first posted in Oct 2023, 7 months after primary completion.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 33 months is above that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2019
First posted
Jul 2, 2019
StartActual
May 18, 2020
Primary completionActual
Mar 15, 2023
CompletionActual
Mar 15, 2023
Results first posted
Oct 27, 2023
Last update
Mar 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04004611
Responsible party
Sponsor
First posted
Jul 2, 2019
Start date
May 18, 2020
Primary completion
Mar 15, 2023
Completion
Mar 15, 2023
Results posted
Oct 27, 2023
Last update
Mar 26, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion